Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Licensing Agreements 20
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Equity Offering 23
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc – Key Competitors 38
Arena Pharmaceuticals Inc – Key Employees 39
Arena Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Sep 01, 2016: Arena Pharmaceutics Announces Formation of Beacon Discovery 41
Financial Announcements 42
Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 42
Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 43
May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 45
Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 46
Nov 07, 2016: Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 08, 2016: Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
May 09, 2016: Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 50
Feb 29, 2016: Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 51
Corporate Communications 53
Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 53
Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 54
Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 55
Jun 15, 2016: Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer 56
May 09, 2016: Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer 57
Product News 58
10/11/2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting 58
06/13/2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name “Etrasimod” for its Drug Candidate APD334 59
Other Significant Developments 60
Jun 30, 2016: Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc, Key Competitors 38
Arena Pharmaceuticals Inc, Key Employees 39
Arena Pharmaceuticals Inc, Other Locations 40
Arena Pharmaceuticals Inc, Subsidiaries 40